Clinical trial
Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5…
NCT00196976 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00196976 |
|---|---|
| Title | Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old |
| Official title | Evaluate the Immunogenicity, Reactogenicity, Safety of 4 Different Formulations of GSK Biologicals' Conjugate Vaccine (MenACWY) vs 1 Dose of MenC-CRM197 or Mencevax™ ACWY in Children Aged 12-14 Months & 3-5 Years |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Meningococcal |
| Intervention type | Biological |
| Interventions | Conjugated meningococcal ACWY-TT (vaccine), DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib), DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™), Meningitec™, Mencevax™ACWY |
| Enrollment | 461 |
| Start date | Mar 24, 2005 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 3, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Jun 8, 2018 |
| Countries | Austria, Greece |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: